Solutions

Clinical solutions

Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions

Consulting & Commercial

Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data

Case studies
Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

Technologies
Technology solutions from early phase through to post-marketing.
Sectors

Sectors

ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

Read more

Biotech Government and Public Health Medical Device Pharmaceuticals

Biotech
Developing transformative therapies requires a flexible approach.

ICON and You
Partners making a difference.
Therapeutics

Therapeutics

Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology

Cross-therapeutics

Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health

Obesity
A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

Therapeutics insights
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
Insights

Insights

Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel

From bottlenecks to breakthroughs
Human-centred strategies for faster study starts

More than monitoring
How modern monitoring paradigms impact CRA roles

Meeting requirements for Joint Clinical Assessments
A planning guide for health technology developers
News & Events

News & Events

ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

Read more

Press releases In the News Mediakit Awards Events Webinars Social media

Best practices in global flow cytometry quality control and harmonisation
5 March 2026. Register today.

When patients lead: Breaking barriers in ultra-rare disease drug development
3 March 2026. Register today.
About ICON

About ICON

Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality

ICON for

Patients Volunteers Investigators Jobs & Careers Investors Suppliers

Sustainability, charity, inclusion and belonging
ICON Cares is our commitment to making a positive impact on our people, environment and our community.

ICON at a glance
Delivering successful outcomes across the clinical development lifecycle.

Careers
Investors
Contact
日本語
简体中文

Home
News & Events
Social media

Social media

Showing 817 - 828 of 955 results for "*"

ICON is honoured to be recognised on TIME and Statista’s World’s Best Companies of 2025 list for the third consecutive year. This achievement is a testament to our people, our values, and our vision for a better future. ...

24 Sep

ICON Plc

Operationalizing new outcome measures in obesity trials is challenging. From selecting the right COAs and DHTs to ensuring clean, high-quality data, every choice impacts trial outcomes. Our upcoming live webinar will pr...

Biomarkers aren’t just supporting drug development, they’re driving it. This expert-led report produced in conjunction with Drug Target Review explores how biomarker science is advancing trial design, accelerating clinic...

ICON recognises #WorldCancerResearchDay to raise awareness of cancer which causes 1 in 6 deaths globally. In the past 5 years, we have participated in 844 oncology and haematologic malignancy Phase 1-4 clinical studies, ...

24 Sep

ICON Plc

In recognition of World Cancer Research Day, ICON’s Patient-Centred Outcomes (PCO) team proudly highlights its ongoing commitment to advancing oncology research. With a dedicated team of over 45 experts across Europe a...

24 Sep

ICON Plc

We’re delighted to announce that Deepali Suri has joined as President of ICON Biotech. With a proven track record in clinical development, operational excellence, and digital innovation, Deepali will lead our support for...

23 Sep

ICON Plc

ICON has recently carried out a comparison of the four most commonly used formulae to adjust the QT-interval for heart rate in healthy subjects. We analysed ECG data from over 22,000 healthy volunteers in phase 1 tria...

23 Sep

ICON Plc

At tomorrow's OCT Southern California, Madelaine MacKay, ICON’s Senior Director, Product Delivery, will take part in an insightful AI panel discussion. As AI continues to reshape the clinical research industry, this pane...

23 Sep

ICON Plc

ICON’s Regulatory Affairs team is proud to sponsor #RAPSConvergence 2025, the leading event for regulatory professionals kicking off October 7th in Pittsburgh, PA. Visit us at booth 409 and meet the team. Venkat Sunkar...

23 Sep